Merck Puffs Up Respiratory Portfolio With EU Rights To Nycomed's Daxas
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck acquires rights to the oral COPD medication in Canada and Europe, where approval appears imminent after Daxas received a positive CHMP nod.
You may also be interested in...
NICE Stuns Merck With Demand For Additional Daxas Trial
NICE says it wants Merck to carry out an additional clinical trial of Daxas in conjunction with triple therapy for COPD, if the company is to get its drug into the NHS.
NICE Stuns Merck With Demand For Additional Daxas Trial
NICE says it wants Merck to carry out an additional clinical trial of Daxas in conjunction with triple therapy for COPD, if the company is to get its drug into the NHS.
Forest/Nycomed's Daliresp Reaches The Market, But For Fewer Patients Than Expected
The narrowed indication granted for Forest Laboratories Inc.'s newly approved chronic obstructive pulmonary disease drug Daliresp (roflumilast) means that a quarter of all diagnosed COPD patients, or three million people, will be eligible for treatment, the firm said.